DATA GRAPHICS | Data Byte
I&I is the new hotness in East-to-West deals
While oncology still dominates, a timeline of deals shows Western companies are increasingly turning to Asia for immunology and inflammation
Innovation in I&I is emerging as a key driver of Asia-to-West dealmaking, as Western biotechs and pharmas expand their focus beyond oncology.
Of 31 immunology and inflammation deals disclosed since 1Q23, 14 (45%) have been announced since the start of 4Q24. That contrasts with a much more steady pace of deals in other indications; only 26% of the cancer deals in the dataset fell in that timeframe. ...